Compare the efficacy and safety of two combination regimens of miltefosine and paromomycin with the current standard treatment
current phase of drug development
updated 1 Jun 2021
Based on the good efficacy of the miltefosine and paromomycin (MF+PM) combination therapy in South Asia, and on the need for an alternative and safer treatment to replace sodium stibogluconate, a Phase III study was launched in 2018 to compare two different combination regimens of miltefosine and paromomycin against the current standard visceral leishmaniasis treatment, sodium stibogluconate and paromomycin.
If these new combinations are proven safe and effective, treatment would no longer rely on sodium stibogluconate, an injectable drug, but would be replaced with miltefosine, an oral drug. A safer, more field-adapted, patient-friendly treatment would particularly benefit children, who represent a high proportion of the population at risk in East Africa.
News & press releases
Get our latest news, personal stories, research articles, and job opportunities.